



Jon Gerrard MLA River Heights
41A-450 Broadway R3C 0V8
jon.gerrard@leg.gov.mb.ca

The Honourable Heather Stefanson
Minister of Health and Seniors Care
302-450 Broadway
Winnipeg, MB
R3C 0V8
minhsc@leg.gov.mb.ca

January 27, 2021

Dear Minister Stefanson and Dr. Roussin,

Research is a critical component of the effort to reduce and eliminate the SARS-CoV2 virus and to reduce and eliminate morbidity and mortality from SARS-CoV2.

For example, we are seeing this in the recently reported results of the research trial using heparin which was led by Manitoba's Dr. Ryan Zarychanski which show benefit from the use of heparin. I am writing to ask the status of research using Ivermectin in Manitoba, and also about plans for the use of ivermectin and plans to ensure enough supply of Ivermectin should it become the standard of care for prophylaxis and treatment of COVID-19.

In brief, the evidence in support of the use of Ivermectin has been growing as a result of multiple randomized clinical trials in addition to various observational trials.

The randomized controlled trials have shown substantial decreases in infections, in morbidity and in mortality. As an example, in the metanalysis of Dr. Andrew Hill (see link below) there was a 75% decrease in mortality. These trials also show substantial decreases in viral load in treated patients compared to controls.

The widespread use of Ivermectin may have been a significant reason for dramatic reductions in mortality in specific locations where it has been used widely. These include Bihar and Utter Pradesh in India, Chiapas in Mexico, 8 states in Peru, and 3 cities in Brazil.

There are a number of additional trials to be reported in the near future. It is possible that Ivermectin may soon become the standard of care in addressing COVID-19. What is the status of Manitoba's supply of this drug if it were to become widely needed here in the near future?

Sincerely,

Dr. Jon Gerrard
MLA-River Heights
CC Dr. Brent Roussin

For further information see these articles and reports:

Studies in South America

<https://covid19criticalcare.com/i-mask-prophylaxis-treatment-protocol/epidemiologic-analyses-on-covid19-and-ivermectin/>

Dr. Andrew Hill's metaanalysis showing a 43% increased rate of clinical recovery from COVID-19, and an 83% improvement in survival rate.

FRCCC analysis

<https://www.frontiersin.org/articles/10.3389/fphar.2021.643369/abstract>

The story in India

<https://trialsitenews.com/an-unlikely-nation-is-kicking-this-pandemic-guess-which-then-why/>